Contents
22 January 2019
Vol 12, Issue 565
Vol 12, Issue 565
Focus
- Why geneticists stole cancer research even though cancer is primarily a signaling disease
Technological advances in protein detection will enable breakthroughs in precision cancer medicine.
Research Article
- Transcriptional repressor REST drives lineage stage–specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma
Functions of the transcription factor REST in SHH-type medulloblastoma may reveal new therapeutic targets.
Research Resource
- Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
Analysis of adaptive kinome activity reveals paths of drug resistance in HER2-positive breast cancer.
Review
- Illuminating the dark phosphoproteome
Identifying the targets of “dark” kinases will provide new biological and disease insights.
Editors' Choice
- Putting the squeeze on ERK signaling
Cell compaction induces epithelial cell elimination by reducing ERK activation.
About The Cover
Online Cover This week features a Review that discusses how assigning targets to kinases, particularly those with few or no known substrates, and functionally annotating the phosphoproteome will provide new biological and disease insights. A complementary Focus emphasizes the need to shift from genetics-based approaches to protein- and signaling-centric approaches to realize the potential of precision cancer medicine. The image shows a three-dimensional phylogenetic tree of kinases color-coded by family. The node size and illumination represent the number of known targets for each kinase. [Image: Tim Burykin/Sydney University, Sydney, Australia]
